| Code | CSB-RA001986MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to PMG-1015 for research targeting amphiregulin (AREG), a member of the epidermal growth factor (EGF) family. AREG functions as a ligand for the epidermal growth factor receptor (EGFR), playing crucial roles in cell proliferation, differentiation, and tissue repair processes. Through autocrine and paracrine signaling mechanisms, amphiregulin regulates epithelial cell growth and wound healing responses. Aberrant AREG expression has been implicated in various pathological conditions, including cancer progression, tumor metastasis, and inflammatory diseases. Elevated amphiregulin levels are particularly associated with colorectal cancer, breast cancer, and other malignancies where EGFR signaling contributes to tumor development and therapeutic resistance.
The reference antibody PMG-1015 has been utilized in research investigating AREG-mediated signaling pathways and its role in disease pathogenesis. This biosimilar antibody serves as a valuable tool for studying amphiregulin biology, examining EGFR pathway activation, and exploring potential therapeutic interventions in AREG-dependent disease models. It supports investigations into tumor microenvironment interactions and regenerative medicine applications.
There are currently no reviews for this product.